A Phase I Trial to Evaluate the Safety and Immunogenicity of an Influenza Vaccination Strategy Including a H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs H3N2 M2SR influenza vaccine-FluGen (Primary) ; Influenza virus vaccine
- Indications Influenza A virus infections
- Focus Adverse reactions
- 24 Oct 2019 Planned End Date changed from 31 Jul 2019 to 31 Oct 2020.
- 24 Oct 2019 Planned primary completion date changed from 31 Jul 2019 to 31 Oct 2020.
- 24 Oct 2019 Status changed from recruiting to active, no longer recruiting.